Phase II study of propranolol feasibility with neoadjuvant chemotherapy in patients with newly diagnosed breast cancer
ConclusionOur results support the feasibility of combining propranolol (up to 80 mg ER) with neoadjuvant taxane/anthracycline-based chemotherapy.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | HER2 | Hormones | Inderal | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy | Study | Women